{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:16:51Z","timestamp":1783005411602,"version":"3.54.5"},"reference-count":101,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Rheumatoid arthritis (RA) is a systemic rheumatic disease. Its most prominent characteristic is synovitis, which manifests clinically as arthritis, resulting in joint damage. Interstitial lung disease (ILD) is an extraarticular manifestation of RA that hinders therapeutic goals, affects life prognosis, and can be worsened by the administration of disease-modifying antirheumatic drugs (DMARDs). Therefore, proper management of ILD, including consideration of risk factors such as the systemic disease activity of RA and autoantibodies, and early detection with high-resolution computed tomography are required at the introduction of DMARDs. Methotrexate, a class of DMARD used as the anchor drug for RA treatment, has been recognized as likely to worsen RA-ILD. However, there are currently reports suggesting that methotrexate may have beneficial effects on RA-ILD. Conversely, several studies have also shown exacerbations of ILD with the administration of biological DMARDs, which are thought of as tolerable for patients with RA-ILD. Rheumatologists should be wary of emergence or changes in the activity of ILD and arthritis during treatment of any kind with DMARDs. Further studies are warranted to clarify underlying ethnic factors, such as the possible effects of antimelanoma differentiation-associated gene 5 antibodies on RA-ILD.<\/jats:p>","DOI":"10.3390\/jcm15135175","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:43:14Z","timestamp":1783003394000},"page":"5175","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recent Knowledge Regarding the Epidemiology, Exacerbating Factors, and Treatment of Rheumatoid Arthritis Complicated by Interstitial Lung Disease"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2366-3566","authenticated-orcid":false,"given":"Yoshiro","family":"Horai","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Sasebo City General Hospital, Sasebo 857-8511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/rheumatology\/keae701","article-title":"Poor prognostic factors and unmet needs in rheumatoid arthritis","volume":"64","author":"Smolen","year":"2025","journal-title":"Rheumatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"616","DOI":"10.31138\/mjr.150425.smr","article-title":"Impact of Seropositivity on Mortality and Extra-Articular Manifestations in Rheumatoid Arthritis: A Nationwide Propensity-Matched Cohort Study","volume":"31","author":"Alomari","year":"2025","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1007\/s10067-024-07068-2","article-title":"Use of methotrexate and TNF inhibitors in patients with rheumatoid arthritis-associated interstitial lung disease: A survey of rheumatologists","volume":"43","author":"Park","year":"2024","journal-title":"Clin. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s13075-025-03674-w","article-title":"Screening for rheumatoid arthritis-associated interstitial lung disease using low-dose CT: An emerging approach\u2014An observational prospective case-control study","volume":"27","author":"Fritsch","year":"2025","journal-title":"Arthritis Res. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Aramaki, T., Kojima, K., Michituji, T., Takatani, A., Terada, K., Eguchi, K., Ueki, Y., Iwamoto, N., and Kawakami, A. (2026). Interstitial lung disease constitutes a significant treatment burden in patients with rheumatoid arthritis. Front. Med., 13.","DOI":"10.3389\/fmed.2026.1756931"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.42861","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.ard.2026.01.023","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update","volume":"85","author":"Smolen","year":"2026","journal-title":"Ann. Rheum. Dis."},{"key":"ref_8","first-page":"S179","article-title":"Methotrexate as the \u201canchor drug\u201d for the treatment of early rheumatoid arthritis","volume":"21","author":"Pincus","year":"2003","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/mr\/road098","article-title":"Japan College of Rheumatology guidance for the use of methotrexate in patients with rheumatoid arthritis: Secondary publication","volume":"34","author":"Kameda","year":"2024","journal-title":"Mod. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3899\/jrheum.2024-0252","article-title":"Interstitial Lung Disease in Patients with Rheumatoid Arthritis or Psoriatic Arthritis Initiating Biologics and Controls: Data from 5 Nordic Registries","volume":"51","author":"Provan","year":"2024","journal-title":"J. Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1093\/rheumatology\/keaa608","article-title":"Acute exacerbation of rheumatoid arthritis\u2013associated interstitial lung disease: Clinical features and prognosis","volume":"60","author":"Izuka","year":"2021","journal-title":"Rheumatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/rheumatology\/keac651","article-title":"Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease","volume":"62","author":"Kim","year":"2023","journal-title":"Rheumatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2402533","DOI":"10.1183\/13993003.02533-2024","article-title":"ERS\/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease","volume":"67","author":"Antoniou","year":"2026","journal-title":"Eur. Respir. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"105790","DOI":"10.1016\/j.jbspin.2024.105790","article-title":"2024 update of the recommendations of the French Society of Rheumatology for the diagnosis and management of patients with rheumatoid arthritis","volume":"91","author":"Fautrel","year":"2024","journal-title":"Jt. Bone Spine"},{"key":"ref_15","first-page":"1865","article-title":"The Italian Society for Rheumatology guidelines for the treatment of patients with rheumatoid arthritis and interstitial lung disease","volume":"78","author":"Crotti","year":"2026","journal-title":"Reumatismo"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.resinv.2021.04.011","article-title":"2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease","volume":"59","author":"Kondoh","year":"2021","journal-title":"Respir. Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e851","DOI":"10.1016\/S2665-9913(25)00158-4","article-title":"Risk Factors for Interstitial Lung Disease in Early Rheumatoid Arthritis and External Validation of Screening Strategies: A Cross-Sectional Analysis of the Prospective SAIL-RA Cohort in the USA","volume":"7","author":"McDermott","year":"2025","journal-title":"Lancet Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"rkag045","DOI":"10.1093\/rap\/rkag045","article-title":"The prevalence of interstitial lung disease in rheumatoid arthritis: A systematic review","volume":"10","author":"Vermant","year":"2026","journal-title":"Rheumatol. Adv. Pract."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Tharwani, A., and Ribeiro Neto, M.L. (2025). Updates in Diagnostic Tools for ILD. J. Clin. Med., 14.","DOI":"10.3390\/jcm14092924"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/acr.25347","article-title":"American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Care Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.chest.2025.11.033","article-title":"Subclinical Interstitial Lung Disease in Rheumatoid Arthritis: Implications for Early Detection and Management","volume":"169","author":"Ormsby","year":"2025","journal-title":"Chest"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5853","DOI":"10.1093\/rheumatology\/keaf380","article-title":"Risk of total and cause-specific mortality in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis","volume":"64","author":"Zhang","year":"2025","journal-title":"Rheumatology"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Mori, S., Sakai, F., Hasegawa, M., Nakamura, K., and Sugahara, K. (2025). Mortality and Predictive Factors for Death Following the Diagnosis of Interstitial Lung Disease in Patients with Rheumatoid Arthritis: A Retrospective, Long-Term Follow-Up Study. J. Clin. Med., 14.","DOI":"10.3390\/jcm14041380"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.2169\/internalmedicine.5200-24","article-title":"Current Trends in Computed Tomography Practices in Japan and the Role of Referring Physicians in Radiation Exposure Management","volume":"64","author":"Uruma","year":"2025","journal-title":"Intern. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2332406","DOI":"10.1080\/07853890.2024.2332406","article-title":"The prevalence and risk factors of rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis","volume":"56","author":"Wang","year":"2024","journal-title":"Ann. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40744-025-00769-3","article-title":"Influence of Rheumatoid Factors on the Efficacy of TNF Inhibitor Therapy in Patients with Rheumatoid Arthritis","volume":"12","author":"Nagayasu","year":"2025","journal-title":"Rheumatol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1093\/rheumatology\/keae598","article-title":"Predictors of the effectiveness of first-line CTLA4-Ig in patients with RA: The FIRST registry","volume":"64","author":"Kobayashi","year":"2025","journal-title":"Rheumatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1007\/s10067-025-07627-1","article-title":"Nonlinear association between rheumatoid factor and interstitial lung disease risk in patients with rheumatoid arthritis","volume":"44","author":"Li","year":"2025","journal-title":"Clin. Rheumatol."},{"key":"ref_30","first-page":"e2024005","article-title":"Characteristics of chest high-resolution computed tomography in patients with anti-aminoacyl-tRNA synthetase antibody-positive interstitial lung disease","volume":"41","author":"Mima","year":"2024","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"322","DOI":"10.7861\/clinmedicine.17-4-322","article-title":"Idiopathic inflammatory myopathies\u2014A guide to subtypes, diagnostic approach and treatment","volume":"17","author":"Oldroyd","year":"2017","journal-title":"Clin. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Oka, S., Higuchi, T., Furukawa, H., Shimada, K., Okamoto, A., Fujimori, M., Hashimoto, A., Komiya, A., Saisho, K., and Yoshikawa, N. (2024). Serum Anti-Aminoacyl-Transfer Ribonucleic Acid Synthetase Antibody Levels Are Involved in Rheumatoid Arthritis Complicated with Interstitial Lung Disease. J. Clin. Med., 13.","DOI":"10.3390\/jcm13226761"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/rheumatology\/ker518","article-title":"The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM","volume":"51","author":"Koga","year":"2012","journal-title":"Rheumatology"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Oka, S., Higuchi, T., Furukawa, H., Shimada, K., Okamoto, A., Hashimoto, A., Komiya, A., Saisho, K., Yoshikawa, N., and Katayama, M. (2023). Antibodies against Serum Anti-Melanoma Differentiation-Associated Gene 5 in Rheumatoid Arthritis Patients with Chronic Lung Diseases. Medicina, 59.","DOI":"10.3390\/medicina59020363"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2169\/internalmedicine.1613-18","article-title":"Rheumatoid Arthritis Complicated with Anti-melanoma Differentiation-associated Gene 5 Antibody-positive Interstitial Pneumonia","volume":"58","author":"Matsumoto","year":"2019","journal-title":"Intern. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/mrcr\/rxae013","article-title":"Development of anti-MDA5 autoantibody-positive dermatomyositis following the use of etanercept biosimilar in rheumatoid arthritis","volume":"8","author":"Okazaki","year":"2024","journal-title":"Mod. Rheumatol. Case Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 ACR-EULAR classification criteria for primary Sj\u00f6gren\u2019s syndrome: A consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Horai, Y., Kurushima, S., Shimizu, T., Nakamura, H., and Kawakami, A. (2025). A Review of the Impact of Sj\u00f6gren\u2019s Syndrome and\/or the Presence of Anti-Ro\/SS-A Antibodies on Therapeutic Strategies for Rheumatoid Arthritis. J. Clin. Med., 14.","DOI":"10.3390\/jcm14020568"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Ma, Y., Gu, C., Li, Q., and Lu, L. (2025). Dual vs. isolated anti-Ro antibody positivity in rheumatoid arthritis. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1661334"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Nakano, K., Fujita, S., Hiramatsu-Asano, S., Nagasu, A., Tsuji, S., Koide, Y., Yamada, M., Mizuta, Y., Ikeda, M., and Hirano, H. (2025). Clinical Significance of Antinuclear Antibodies in Patients with Rheumatoid Arthritis: From SETOUCHI-RA Registry. J. Clin. Med., 14.","DOI":"10.3390\/jcm14051553"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Horai, Y., Kurushima, S., and Kawakami, A. (2025). Current Diagnosis and Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Review Including a Comparison of Characteristics in Europe and Japan. J. Clin. Med., 14.","DOI":"10.3390\/jcm14051724"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"keag072","DOI":"10.1093\/rheumatology\/keag072","article-title":"ANCA testing in real-world clinical practice: Diagnostic performance and predictive value in a Spanish cohort","volume":"65","year":"2026","journal-title":"Rheumatology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/annrheumdis-2021-221795","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis","volume":"81","author":"Robson","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/annrheumdis-2021-221796","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis","volume":"81","author":"Suppiah","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/annrheumdis-2021-221794","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis","volume":"81","author":"Grayson","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2332\/allergolint.R-07-141","article-title":"ANCA-associated vasculitis: Diagnostic and therapeutic strategy","volume":"56","author":"Ozaki","year":"2007","journal-title":"Allergol. Int."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Huang, Z., Wu, T., Lu, R., Zhou, H., Zhang, Y., Huang, L., Gan, Y., and He, H. (2025). Prevalence and clinical significance of anti-neutrophil cytoplasmic antibodies in rheumatoid arthritis-associated interstitial lung disease. BMC Pulm. Med., 25.","DOI":"10.1186\/s12890-025-03644-7"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.3899\/jrheum.161432","article-title":"Anti-carbamylated Protein Antibodies Are Detectable in Various Connective Tissue Diseases","volume":"44","author":"Nakabo","year":"2017","journal-title":"J. Rheumatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/annrheumdis-2019-216709","article-title":"Anti-carbamylated proteins antibody repertoire in rheumatoid arthritis: Evidence of a new autoantibody linked to interstitial lung disease","volume":"79","author":"Gomara","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1007\/s10753-022-01661-w","article-title":"Serum Uric Acid as a Diagnostic Biomarker for Rheumatoid Arthritis\u2013Associated Interstitial Lung Disease","volume":"45","author":"Wang","year":"2022","journal-title":"Inflammation"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2576636","DOI":"10.1080\/07853890.2025.2576636","article-title":"A clinically applicable method for early interstitial lung disease detection in incident rheumatoid arthritis cases: Integration of protein biomarkers and clinical factors","volume":"57","author":"Gou","year":"2025","journal-title":"Ann. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5152\/eurjrheum.2025.24087","article-title":"Profile of Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Single-Center Study","volume":"12","author":"Alduraibi","year":"2025","journal-title":"Eur. J. Rheumatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.semarthrit.2021.07.002","article-title":"MUC5B promoter variant rs35705950 and rheumatoid arthritis associated interstitial lung disease survival and progression","volume":"51","author":"Juge","year":"2021","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"152098","DOI":"10.1016\/j.semarthrit.2022.152098","article-title":"Genetic, social, and environmental risk factors in rheumatoid arthritis-associated interstitial lung disease","volume":"57","author":"Wheeler","year":"2022","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Guo, L., Wang, J., Li, J., Yao, J., and Zhao, H. (2024). Biomarkers of rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1455346"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Xu, J., Zhang, W., Bai, W., Gai, N., Li, J., and Bao, Y. (2025). A multi-biomarker machine learning approach for early prediction of interstitial lung disease in rheumatoid arthritis. BMC Pulm. Med., 25.","DOI":"10.1186\/s12890-025-03855-y"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12931-021-01856-z","article-title":"Factors associated with mortality in rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis","volume":"22","author":"Qiu","year":"2021","journal-title":"Respir. Res."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Groseanu, L., and Ni\u021b\u0103, C. (2024). A Systematic Review of the Key Predictors of Progression and Mortality of Rheumatoid Arthritis-Associated Interstitial Lung Disease. Diagnostics, 14.","DOI":"10.3390\/diagnostics14171890"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.40904","article-title":"Rheumatoid Arthritis Disease Activity Predicting Incident Clinically Apparent Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Prospective Cohort Study","volume":"71","author":"Sparks","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.semarthrit.2013.09.005","article-title":"Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: A systematic literature review","volume":"43","author":"Roubille","year":"2014","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S0140-6736(21)01826-2","article-title":"Treatment of fibrotic interstitial lung disease: Current approaches and future directions","volume":"398","author":"Johannson","year":"2021","journal-title":"Lancet"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1093\/rheumatology\/key208","article-title":"The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis","volume":"58","author":"Holroyd","year":"2019","journal-title":"Rheumatology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e002343","DOI":"10.1136\/rmdopen-2022-002343","article-title":"Analysis of risk factors of mortality in rheumatoid arthritis patients with interstitial lung disease: A nationwide, population-based cohort study in Taiwan","volume":"8","author":"Ng","year":"2022","journal-title":"RMD Open"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e003132","DOI":"10.1136\/bmjopen-2013-003132","article-title":"Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: A retrospective case control study","volume":"3","author":"Hozumi","year":"2013","journal-title":"BMJ Open"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2000337","DOI":"10.1183\/13993003.00337-2020","article-title":"Methotrexate and rheumatoid arthritis associated interstitial lung disease","volume":"57","author":"Juge","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e028466","DOI":"10.1136\/bmjopen-2018-028466","article-title":"Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts","volume":"9","author":"Kiely","year":"2019","journal-title":"BMJ Open"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3899\/jrheum.210322","article-title":"Tacrolimus in Patients with Interstitial Pneumonia Associated with Polymyositis or Dermatomyositis: Interim Report of Postmarketing Surveillance in Japan","volume":"49","author":"Kuwana","year":"2022","journal-title":"J. Rheumatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2177\/jsci.31.62","article-title":"A case report of rheumatoid arthritis complicated with rapidly progressive interstitial pneumonia, multiple bullae and pneumomediastinum, which was successfully treated with tacrolimus","volume":"31","author":"Ochi","year":"2008","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3109\/s10165-008-0034-3","article-title":"Tacrolimus-induced lung injury in a rheumatoid arthritis patient with interstitial pneumonitis","volume":"18","author":"Miwa","year":"2008","journal-title":"Mod. Rheumatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/ard.2009.120626","article-title":"BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: Results from the British Society for Rheumatology Biologics Register","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2169\/internalmedicine.50.4748","article-title":"Adalimumab-induced interstitial pneumonia with an improvement of pre-existing rheumatoid arthritis-associated lung involvement","volume":"50","author":"Komiya","year":"2011","journal-title":"Intern. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1590\/S1806-37132014000100012","article-title":"Adalimumab-Induced Acute Interstitial Lung Disease in a Patient with Rheumatoid Arthritis","volume":"40","author":"Dias","year":"2014","journal-title":"J. Bras. Pneumol."},{"key":"ref_75","first-page":"1151","article-title":"Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis","volume":"34","author":"Hagiwara","year":"2007","journal-title":"J. Rheumatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2710.2010.01234.x","article-title":"Eternacept for the treatment of patients with rheumatoid arthritis and concurrent interstitial lung disease","volume":"37","author":"Horai","year":"2012","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1093\/rheumatology\/ket175","article-title":"A case of certolizumab-induced interstitial lung disease in a patient with rheumatoid arthritis","volume":"52","author":"Glaspole","year":"2013","journal-title":"Rheumatology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40744-024-00737-3","article-title":"Effect of Ozoralizumab Administration with or without Methotrexate in Patients with Rheumatoid Arthritis: A Post-Hoc Analysis","volume":"12","author":"Tanaka","year":"2025","journal-title":"Rheumatol. Ther."},{"key":"ref_79","first-page":"193","article-title":"Different phenotypic manifestations between Brazilian and Japanese anti-MDA5 antibody-positive dermatomyositis: An international tricentric longitudinal study","volume":"43","author":"Faria","year":"2025","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_80","first-page":"299","article-title":"Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients","volume":"61","author":"Loricera","year":"2022","journal-title":"Rheumatology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"152795","DOI":"10.1016\/j.semarthrit.2025.152795","article-title":"Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: A post hoc pooled analysis from a compendium of clinical trials","volume":"74","author":"Sparks","year":"2025","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Shoda, T., Kotani, T., Koyama, M., Yoshikawa, A., Wada, Y., Makino, H., Osuga, K., and Takeuchi, T. (2024). The Therapeutic Efficacy of Abatacept for Rheumatoid Arthritis-Associated Interstitial Lung Disease: Insights from a 12-Month Trial Using Semi-Quantitative Chest High-Resolution Computed Tomography Imaging. J. Clin. Med., 13.","DOI":"10.3390\/jcm13195871"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"keag023","DOI":"10.1093\/rheumatology\/keag023","article-title":"Progressive interstitial lung disease associated with rheumatoid arthritis and abatacept: Data from a multicentre cohort of 526 patients","volume":"65","year":"2026","journal-title":"Rheumatology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/14397595.2018.1481566","article-title":"Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept","volume":"29","author":"Mochizuki","year":"2019","journal-title":"Mod. Rheumatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1136\/annrheumdis-2015-208426","article-title":"Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)","volume":"75","author":"Kaneko","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/imj.14670","article-title":"Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: A multicentre retrospective study","volume":"50","author":"Manfredi","year":"2020","journal-title":"Intern. Med. J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1007\/s00296-010-1525-z","article-title":"A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab","volume":"32","author":"Kawashiri","year":"2012","journal-title":"Rheumatol. Int."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00296-016-3478-3","article-title":"Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: A retrospective, case-control study","volume":"36","author":"Akiyama","year":"2016","journal-title":"Rheumatol. Int."},{"key":"ref_89","first-page":"451","article-title":"Long-term efficacy of sarilumab on the progression of interstitial lung disease in rheumatoid arthritis: The KEIO-RA cohort and literature review","volume":"43","author":"Suzuki","year":"2025","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Kurushima, S., Koga, T., Umeda, M., Iwamoto, N., Miyashita, R., Tokito, T., Okuno, D., Yura, H., Ishimoto, H., and Kido, T. (2024). Impact of Janus kinase inhibitors and methotrexate on interstitial lung disease in rheumatoid arthritis patients. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1501146"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Suzuki, K., Akiyama, M., Shimanuki, K., and Kaneko, Y. (2026). Impact of concomitant methotrexate on JAK inhibitors in rheumatoid arthritis-associated interstitial lung disease: A retrospective single-centre study from the KEIO-RA cohort. Clin. Exp. Rheumatol., ahead of print.","DOI":"10.55563\/clinexprheumatol\/tiu2h4"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Wang, S., Li, Y., Tang, Y., Xie, W., Zhang, Y., and Li, Q. (2023). A prospective observational cohort study of the efficacy of tofacitinib plus iguratimod on rheumatoid arthritis with usual interstitial pneumonia. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1215450"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Zhu, Y., Ye, Y., Zhou, W., Zheng, X., Xie, W., and Wu, Z. (2026). Dual targeting of joint and lung disease: Efficacy of tofacitinib plus iguratimod combination in progressive fibrosing rheumatoid arthritis-associated interstitial lung disease. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1624125"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e70023","DOI":"10.1002\/rcr2.70023","article-title":"Successful treatment of rheumatoid arthritis-associated interstitial lung disease with filgotinib: A case report on janus kinase 1 inhibition","volume":"12","author":"Sunaga","year":"2024","journal-title":"Respirol. Case Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e70502","DOI":"10.1002\/rcr2.70502","article-title":"Rheumatoid Arthritis Preceded by Interstitial Lung Disease Controlled by Long-Term Treatment with the Janus Kinase 1-Selective Inhibitor, Filgotinib: A Case Report","volume":"14","author":"Sato","year":"2026","journal-title":"Respirol. Case Rep."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Nishii, Y., Okamoto, M., Zaizen, Y., Kojima, T., Nouno, T., Naitou-Nishida, Y., Matsuo, N., Takeoka, H., Ishida, M., and Nakamura, M. (2023). Successful Treatment of a Patient with Drug-Refractory Rheumatoid Arthritis-Associated Interstitial Lung Disease with Upadacitinib: A Case Report. Medicina, 59.","DOI":"10.3390\/medicina59111960"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/14712598.2025.2567868","article-title":"Efficacy and safety of rituximab in rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis","volume":"25","author":"Ines","year":"2025","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","article-title":"Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: A randomised, double-blind, placebo-controlled, phase 2 study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive Fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Mena-V\u00e1zquez, N., Rojas-Gimenez, M., Romero-Barco, C.M., Manrique-Arija, S., Francisco, E., Aguilar-Hurtado, M.C., A\u00f1\u00f3n-O\u00f1ate, I., P\u00e9rez-Albaladejo, L., Ortega-Castro, R., and Godoy-Navarrete, F.J. (2021). Predictors of Progression and Mortality in Patients with Prevalent Rheumatoid Arthritis and Interstitial Lung Disease: A Prospective Cohort Study. J. Clin. Med., 10.","DOI":"10.3390\/jcm10040874"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5175\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:49:41Z","timestamp":1783003781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":101,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15135175"],"URL":"https:\/\/doi.org\/10.3390\/jcm15135175","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]}}}